1887

Abstract

-associated diarrhoea (CDAD) is the most common hospital-acquired diarrhoea, and is a major type of gastroenteritis infection in nursing homes and facilities for the elderly. In this study the antimicrobial activity of the two-component lantibiotic, lacticin 3147, against a range of genetically distinct isolates was studied. The bacteriocin exhibited an MIC of 3.6 μg ml for 10 genetically distinct strains isolated from healthy subjects, inflammatory bowel disease patients and culture collection strains. In time-kill studies, 10 c.f.u. ml ATCC 42593 and CDAD isolate DPC 6220 were killed within 120 or 20 min incubation, respectively, at a concentration of 6 μg lacticin ml. Interestingly, addition of lacticin 3147 to exponentially growing cells of ATCC 43593 caused rapid lysis of the cells after an initial lag phase, as measured by the concomitant release of the intracellular enzyme, acetate kinase. The addition of a food-grade, milk-based lacticin containing powder to faecal fermentation demonstrated that lacticin is effective in completely eliminating 10 c.f.u. ml from a model faecal environment within 30 min when present at concentrations as low as 18 μg ml. While other culturable microflora such as total anaerobes, bacteroides, total non-spore-forming anaerobes and total Gram-negative anaerobes were unaffected, populations of lactobacilli and bifidobacteria were reduced by 3 log cycles at bacteriocin levels sufficient to eliminate over 10 e. In light of these findings, the potential of lacticin 3147 for treatment of CDAD is discussed.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47085-0
2007-07-01
2019-12-10
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/7/940.html?itemId=/content/journal/jmm/10.1099/jmm.0.47085-0&mimeType=html&fmt=ahah

References

  1. Aslam, S., Hamill, R. J. & Musher, D. M. ( 2005; ). Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet 5, 549–557.[CrossRef]
    [Google Scholar]
  2. Bartoloni, A., Mantella, A., Goldstein, B. P., Dei, R., Benedetti, M., Sbaragli, S. & Paradisi, F. ( 2004; ). In-vitro activity of nisin against clinical isolates of Clostridium difficile. J Chemother 16, 119–121.[CrossRef]
    [Google Scholar]
  3. Brazier, J. S., Fawley, W., Freeman, J. & Wilcox, M. H. ( 2001; ). Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 48, 741–742.[CrossRef]
    [Google Scholar]
  4. Bricker, E., Garg, R., Nelson, R., Loza, A., Novak, T. & Hansen, J. ( 2005; ). Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 1, CD004610
    [Google Scholar]
  5. Can, M., Besirbellioglu, B. A., Avci, I. Y., Beker, C. M. & Pahsa, A. ( 2006; ). Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit 12, PI19–PI22.
    [Google Scholar]
  6. Cotter, P. D., O'Connor, P. M., Draper, L. A., Lawton, E. M., Deegan, L. H., Hill, C. & Ross, R. P. ( 2005; ). Posttranslational conversion of l-serines to d-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci U S A 102, 18584–18589.[CrossRef]
    [Google Scholar]
  7. Depardieu, F., Kolbert, M., Pruul, H., Bell, J. & Courvalin, P. ( 2004; ). VanD-type vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 48, 3892–3904.[CrossRef]
    [Google Scholar]
  8. Drummond, L. J., McCoubrey, J., Smith, D. G., Starr, J. M. & Poxton, I. R. ( 2003; ). Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 52, 259–263.[CrossRef]
    [Google Scholar]
  9. Fooks, L. J. & Gibson, G. R. ( 2003; ). Mixed culture fermentation studies on the effects of synbiotics on the human intestinal pathogens Campylobacter jejuni and Escherichia coli. Anaerobe 9, 231–242.[CrossRef]
    [Google Scholar]
  10. Franz, C. M., Holzapfel, W. H. & Stiles, M. E. ( 1999; ). Enterococci at the crossroads of food safety?. Int J Food Microbiol 47, 1–24.[CrossRef]
    [Google Scholar]
  11. Gal, M., Northey, G. & Brazier, J. S. ( 2005; ). A modified pulsed-field gel electrophoresis (PFGE) protocol for subtyping previously non-PFGE typeable isolates of Clostridium difficile polymerase chain reaction ribotype 001. J Hosp Infect 61, 231–236.[CrossRef]
    [Google Scholar]
  12. George, R. H., Symonds, J. M., Dimock, F., Brown, J. D., Arabi, Y., Shinagawa, N., Keighley, M. R., Alexander-Williams, J. & Burdon, D. W. ( 1978; ). Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J 1, 695 [CrossRef]
    [Google Scholar]
  13. Goossens, D., Jonkers, D., Stobberingh, E., van den Bogaard, A., Russel, M. & Stockbrugger, R. ( 2003; ). Probiotics in gastroenterology: indications and future perspectives. Scand J Gastroenterol 38, (Suppl. 239), 15–23.[CrossRef]
    [Google Scholar]
  14. Hall, I. C. & O'Toole, E. ( 1935; ). Intestinal flora in new-born infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49, 390–402.[CrossRef]
    [Google Scholar]
  15. Hiramatsu, K. ( 2001; ). Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1, 147–155.[CrossRef]
    [Google Scholar]
  16. Hopkins, M. J. & Macfarlane, G. T. ( 2003; ). Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 69, 1920–1927.[CrossRef]
    [Google Scholar]
  17. Joseph, R., Demeter, D., Vanrentetghem, R., van den Berg, R., Kuiper, E. & Delmee, M. ( 2005; ). First isolation of Clostridium difficile PCR ribotype 027, toxin type 111 in Belgium. Eurosurveillance 10, 274–275.
    [Google Scholar]
  18. Jousimies-Somer, H. R., Summanen, P., Citron, D. M., Baron, E. J., Wexler, H. M. & Finegold, S. M. ( 2002; ). Wandsworth-KTL Anaerobic Bacteriology Manual, pp. 143–164. Belmont, CA: Star Publishing.
  19. Marteau, P. R. ( 2002; ). Probiotics in clinical conditions. Clin Rev Allergy Immunol 22, 255–273.[CrossRef]
    [Google Scholar]
  20. Martin, N. I., Sprules, T., Carpenter, M. R., Cotter, P. D., Hill, C., Ross, R. P. & Vederas, J. C. ( 2004; ). Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 43, 3049–3056.[CrossRef]
    [Google Scholar]
  21. McAuliffe, O., Ryan, M. P., Ross, R. P., Hill, C., Breeuwer, P. & Abee, T. ( 1998; ). Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl Environ Microbiol 64, 439–445.
    [Google Scholar]
  22. McAuliffe, O., Hill, C. & Ross, R. P. ( 2000; ). Each peptide of the two-component lantibiotic lacticin 3147 requires a separate modification enzyme for activity. Microbiology 146, 2147–2154.
    [Google Scholar]
  23. McFarland, L. V. ( 2005; ). Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol 54, 101–111.[CrossRef]
    [Google Scholar]
  24. Morgan, S. M., Galvin, M., Kelly, J., Ross, R. P. & Hill, C. ( 1999; ). Development of a lacticin 3147-enriched whey powder with inhibitory activity against foodborne pathogens. J Food Prot 62, 1011–1016.
    [Google Scholar]
  25. Mulligan, M. E., Rolfe, R. D., Finegold, S. M. & George, W. L. ( 1979; ). Contamination of a hospital environment by Clostridium difficile. Curr Microbiol 3, 173–175.[CrossRef]
    [Google Scholar]
  26. Ohl, M. E., Stevermer, J. J., Meadows, S., Tribuna, J. & Chek, K. ( 2005; ). What are effective therapies for Clostridium difficile-associated diarrhea? J Fam Pract 54, 176–178.
    [Google Scholar]
  27. Pelaez, T., Alcala, L., Alonso, R., Rodriguez-Creixems, M., Garcia-Lechuz, J. M. & Bouza, E. ( 2002; ). Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46, 1647–1650.[CrossRef]
    [Google Scholar]
  28. Pepin, J., Valiquette, L., Alary, M. E., Villemure, P., Pelletier, A., Forget, K., Pepin, K. & Chouinard, D. ( 2004; ). Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171, 466–472.[CrossRef]
    [Google Scholar]
  29. Plummer, S., Weaver, M. A., Harris, J. C., Dee, P. & Hunter, J. ( 2004; ). Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7, 59–62.
    [Google Scholar]
  30. Poutanen, S. M. & Simor, A. E. ( 2004; ). Clostridium difficile-associated diarrhea in adults. CMAJ 171, 51–58.[CrossRef]
    [Google Scholar]
  31. Rose, I. ( 1955; ). Acetate kinase of bacteria (acetokinase). Methods Enzymol 1, 591–595.
    [Google Scholar]
  32. Ryan, M. P., Rea, M. C., Hill, C. & Ross, R. P. ( 1996; ). An application in Cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 62, 612–619.
    [Google Scholar]
  33. Ryan, M. P., Ross, R. P. & Hill, C. ( 2001; ). Strategy for manipulation of cheese flora using combinations of lacticin 3147-producing and -resistant cultures. Appl Environ Microbiol 67, 2699–2704.[CrossRef]
    [Google Scholar]
  34. Seal, D., Borriello, S. P., Barclay, F., Welch, A., Piper, M. & Bonnycastle, M. ( 1987; ). Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6, 51–53.[CrossRef]
    [Google Scholar]
  35. Simpson, P. J., Stanton, C., Fitzgerald, G. F. & Ross, R. P. ( 2003; ). Genomic diversity and relatedness of bifidobacteria isolated from a porcine cecum. J Bacteriol 185, 2571–2581.[CrossRef]
    [Google Scholar]
  36. Valiquette, L., Low, D. E., Pepin, J. & McGeer, A. ( 2004; ). Clostridium difficile infection in hospitals: a brewing storm. CMAJ 171, 27–29.[CrossRef]
    [Google Scholar]
  37. van Dissel, J. T., de Groot, N., Hensgens, C. M., Numan, S., Kuijper, E. J., Veldkamp, P. & van 't Wout, J. ( 2005; ). Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54, 197–205.[CrossRef]
    [Google Scholar]
  38. Wiedemann, I., Bottiger, T., Bonelli, R. R., Wiese, A., Hagge, S. O., Gutsmann, T., Seydel, U., Deegan, L., Hill, C. & other authors ( 2006; ). The mode of action of the lantibiotic lacticin 3147 – a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 61, 285–296.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47085-0
Loading
/content/journal/jmm/10.1099/jmm.0.47085-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error